Article
Synthetic lethality of decitabine plus ATR inhibition for TP53-mutated AML.
Blood advances - 14 Apr 2026
Baeten Jeremy T, Agashe Sumedha, Tabet Imene, Wooldridge Jack T, Carter Amber, Butler Jamie N, Miller Christopher A, Helton Nicole, Quinet Annabel, Johansson Kimberly B, Yang Yichan, Uy Geoffrey L, Vindigni Alessandro, Link Daniel C
Abstract excerpt
ABSTRACT: TP53 mutations are found in 10% to 15% of myeloid neoplasms and are associated with a dismal prognosis. Although hypomethylating agents (HMAs), such as decitabine, are active in TP53-mutated myeloid neoplasms (TP53-MN), mutation clearance is rarely complete and nearly all patients relapse. Molecular determinants of response to HMAs in TP53-MN are poorly understood. Here, we show that decitabine induces...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.